Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 16/20 | 0.62 |
| ▸ | MTNR1B | P49286 | 16/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2242754 | 0.90 | MTNR1A (0.64) | MTNR1AMTNR1BKDM4EALDH1A1HPGD | |
| SCHEMBL2243518 | 0.89 | MTNR1A (0.63) | MTNR1AMTNR1BKDM4EALDH1A1HPGD | |
| SCHEMBL2244974 | 0.88 | MTNR1A (0.65) | MTNR1AMTNR1BKDM4EALDH1A1HPGD | |
| SCHEMBL2240927 | 0.84 | MTNR1A (0.69) | MTNR1AMTNR1BKDM4ENQO2TP53 | |
| SCHEMBL2277189 | 0.79 | L3MBTL1 (0.58) | MTNR1AMTNR1BKDM4EALDH1A1HPGD | |
| SCHEMBL31578259 | 0.74 | MTNR1A (1.00) | MTNR1AMTNR1B | |
| SCHEMBL21315640 | 0.74 | MTNR1A (1.00) | MTNR1AMTNR1B | |
| SCHEMBL21315649 | 0.73 | MTNR1A (0.77) | MTNR1AMTNR1B | |
| SCHEMBL29961848 | 0.73 | MTNR1A (0.77) | MTNR1AMTNR1B | |
| SCHEMBL28468940 | 0.73 | MTNR1A (0.83) | MTNR1AMTNR1BALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003682-B2 | Indole compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATORIES SERVIER (FR) | 2011-08-23 | — | — | US | claimed |
| US-20100063128-A1 | Indole compounds, a process for their preparation and pharmaceutical compositions containing them. | LES LABORATOIRES SERVIER (FR) | 2010-03-11 | — | — | US | claimed |
| US-8003682-B2 | Indole compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATORIES SERVIER (FR) | 2011-08-23 | — | — | US | disclosed |
| US-20100063128-A1 | Indole compounds, a process for their preparation and pharmaceutical compositions containing them. | LES LABORATOIRES SERVIER (FR) | 2010-03-11 | — | — | US | disclosed |
| EP-2086933-A2 | NOVEL INDOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Les Laboratoires Servier (FR) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008049996-A2 | NOVEL INDOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063128-A1 | Indole compounds, a process for their preparation and pharmaceutical compositions containing them. | IDO1, TPH1, IDO2 | MTNR1A 112/4885MTNR1B 70/4885KDM4E 2728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.